Managers / Q1 2023 · view latest →
Data Collective IV GP, LLC
CIK 0001664974 · 270 UNIVERSITY AVENUE, PALO ALTO, CA, 94301 · 650-521-7814
Summary
Data Collective IV GP, LLC reported $94M in U.S.-listed holdings across 6 positions for Q1 2023.
The portfolio is heavily concentrated: RXRX alone accounts for 42.2% of reported value.
Compared with Q4 2022, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 77.8% · $73M
- Other · 22.2% · $21M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Rocket Lab USA, Inc. | NEW | +2.93M | 2.93M | +$12M | $12M |
| Mind Medicine (MindMed) Inc. | NEW | +100.3K | 100.3K | +$318,110 | $318,110 |
| Rocket Lab USA, Inc. | SOLD OUT | −2.93M | 0 | −$11M | $0 |
| Mind Medicine (MindMed) Inc. | SOLD OUT | −100.3K | 0 | −$220,770 | $0 |
| ROIVRoivant Sciences Ltd. | TRIMMED | −22.0K | 3.9K | −$177,864 | $28,598 |
| RXRXRecursion Pharmaceuticals, Inc. | HELD | +0 | 5.94M | −$6M | $40M |
| EVLVEvolv Technologies Holdings, Inc. | HELD | +0 | 10.60M | +$6M | $33M |
| Embark Technology, Inc. | HELD | −1 | 3.19M | −$2M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | RXRXRecursion Pharmaceuticals, Inc.history → | COM CL A | 42.23% | $40M | 5.94M |
| 2 | EVLVEvolv Technologies Holdings, Inc.history → | COM CL A | 35.25% | $33M | 10.60M |
| 3 | Rocket Lab USA, Inc. | COM | 12.61% | $12M | 2.93M |
| 4 | Embark Technology, Inc. | COM NEW | 9.54% | $9M | 3.19M |
| 5 | Mind Medicine (MindMed) Inc. | COM NEW | 0.34% | $318,110 | 100.3K |
| 6 | ROIVRoivant Sciences Ltd. | SHS | 0.03% | $28,598 | 3.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $56M | 4 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $59M | 3 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $68M | 4 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $130M | 5 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $87M | 5 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $226M | 6 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $163M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $143M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $115M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 5 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $106M | 5 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $135M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $94M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $95M | 6 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $127M | 5 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $741M | 5 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.